@article{Mohal:2026:10.1016/j.jacc.2025.08.050,
author = {Mohal, JS and Whinnett, ZI and Mohiddin, SA and Malcolmson, J and Elliott, P and Ormerod, JOM and Prasad, S and Ware, JS and Cooper, RM and Tanner, MA and Khalique, Z and Shah, JS and Keene, D and Tangkongpanich, P and Lewis, EC and Sharma, C and Reddy, RK and Naraen, A and Saleh, K and Samways, JW and Howard, JP and Artico, J and Kanagaratnam, P and Francis, DP and Al-Lamee, RK and Varnava, A and Shun-Shin, MJ and Arnold, AD},
doi = {10.1016/j.jacc.2025.08.050},
journal = {J Am Coll Cardiol},
pages = {124--139},
title = {Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial.},
url = {http://dx.doi.org/10.1016/j.jacc.2025.08.050},
volume = {87},
year = {2026}
}

Download

TY  - JOUR
AB  - BACKGROUND: Many patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) have devices capable of right ventricular pacing (RVP). Although pacing can reduce left ventricular outflow tract gradient (LVOTg), it can also reduce cardiac output, so its net effect is variable. OBJECTIVES: We tested whether electromechanical optimization of the programmed atrio-ventricular delay (AVD) allows RVP to achieve a net benefit on symptoms. METHODS: EMORI-HCM (Electromechanically Optimized Right Ventricular Pacing in Obstructive Hypertrophic Cardiomyopathy) is a multicenter, blinded, randomized, crossover trial of AVD-optimized RVP in patients with symptomatic oHCM with resting or provoked gradient of at least 30 mm Hg. Patients with existing dual-chamber devices were randomized to either 3 months of continuous AVD-optimized RVP (intervention) followed by 3 months of backup-only RVP (control), or vice versa. AVD was optimized using a high-precision multiple-alternation protocol assessing acute change in beat-by-beat blood pressure while varying AVD. The primary outcome was symptoms measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. Secondary outcomes include patient-reported daily symptom data collected using a dedicated smartphone application (ORBITA-app), dichotomous patient preference, EQ-5D, exercise capacity, and LVOTg. Patients were blinded to treatment allocation. Symptom assessments were self-administered. Outcome measures were recorded at baseline, crossover, and completion. Analysis was by Bayesian ordinal mixed modeling. RESULTS: Between October 2021 and October 2024, 117 screened patients met the inclusion criteria, of whom 60 were randomized. AVD-optimized RVP improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (+4.5; 95% credible interval [CrI]: 1.3-8.1; probability of benefit [Prbenefit] = 0.997) and daily symptom scores (OR: 1.29; 95% CrI: 0.98-1.68; Prbenefit: 0.969) compared with backup-only pacin
AU  - Mohal,JS
AU  - Whinnett,ZI
AU  - Mohiddin,SA
AU  - Malcolmson,J
AU  - Elliott,P
AU  - Ormerod,JOM
AU  - Prasad,S
AU  - Ware,JS
AU  - Cooper,RM
AU  - Tanner,MA
AU  - Khalique,Z
AU  - Shah,JS
AU  - Keene,D
AU  - Tangkongpanich,P
AU  - Lewis,EC
AU  - Sharma,C
AU  - Reddy,RK
AU  - Naraen,A
AU  - Saleh,K
AU  - Samways,JW
AU  - Howard,JP
AU  - Artico,J
AU  - Kanagaratnam,P
AU  - Francis,DP
AU  - Al-Lamee,RK
AU  - Varnava,A
AU  - Shun-Shin,MJ
AU  - Arnold,AD
DO  - 10.1016/j.jacc.2025.08.050
EP  - 139
PY  - 2026///
SP  - 124
TI  - Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial.
T2  - J Am Coll Cardiol
UR  - http://dx.doi.org/10.1016/j.jacc.2025.08.050
UR  - https://www.ncbi.nlm.nih.gov/pubmed/40892619
VL  - 87
ER  - 

Download